| Study of Felzartamab in Healthy Adult Subjects (NCT06285201) | TJ Biopharma Co., Ltd. | 2024-03-27 |
| Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR (NCT06130540) | Novartis Pharmaceuticals | 2024-03-27 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Deuremidevir Hydrobromide for Suspension (NCT06328400) | Vigonvita Life Sciences | 2024-03-27 |
| NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) (NCT06239272) | St. Jude Children's Research Hospital | 2024-03-27 |
| A Safety and Immunogenicity Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 50 to 70 Years (NCT06335849) | Guangzhou Patronus Biotech Co., Ltd. | 2024-03-27 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 in Healthy Participants (NCT06326606) | MycoMedica Life Sciences PBC | 2024-03-27 |
| Evaluating Clearance of High-Risk HPV and Safety After Administration of ABI-2280 Vaginal Inserts (NCT06491446) | Antiva Biosciences | 2024-03-27 |
| A Study of CS23546 in Subjects With Advanced Tumors (NCT06245122) | Chipscreen Biosciences, Ltd. | 2024-03-27 |
| Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma (NCT06241235) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2024-03-27 |
| The Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells) (NCT06950645) | Sinovac Life Sciences Co., Ltd. | 2024-03-27 |
| A Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-HU6 (NCT06325930) | Rivus Pharmaceuticals, Inc. | 2024-03-26 |
| Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC (NCT06228924) | Tenaya Therapeutics | 2024-03-26 |
| Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC) (NCT06149481) | National Cancer Institute (NCI) | 2024-03-26 |
| A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants. (NCT06310304) | Incyte Corporation | 2024-03-26 |
| Study of IBR733 Cell Injection in Acute Myeloid Leukemia (NCT06234904) | Imbioray (Hangzhou) Biomedicine Co., Ltd. | 2024-03-26 |
| A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL) (NCT06163430) | Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2024-03-26 |
| A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NCT07699328) | Voronoi, Inc | 2024-03-26 |
| A Study of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) in Healthy Adult Panelists (NCT06299696) | Vertex Pharmaceuticals Incorporated | 2024-03-26 |
| Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303) (NCT06308263) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2024-03-25 |
| Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma (NCT06340204) | Peking University People's Hospital | 2024-03-25 |
| A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy Participants (NCT06329895) | Bayer | 2024-03-25 |
| Evaluating the Effect of Tranexamic Acid on the Clinical Outcomes in Patients With Traumatic Brain Injury (NCT06330935) | Mansoura University | 2024-03-25 |
| A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Japanese Male Study Participants (NCT06312566) | UCB Biopharma SRL | 2024-03-25 |
| A Food Effect and Relative Bioavailability Study of Rilzabrutinib in Healthy Participants (NCT06342700) | Sanofi | 2024-03-25 |
| Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (NCT06484829) | Chengdu Zenitar Biomedical Technology Co., Ltd | 2024-03-25 |
| A Phase 1 Study to Assess an Escalating Dose, Multi-prime Vaccination Schedule of R21/Matrix-M™ (NCT06320535) | University of Oxford | 2024-03-25 |
| First in Human Study in Subjects With Obesity, But Otherwise Healthy (NCT06252220) | NeuroBo Pharmaceuticals Inc. | 2024-03-25 |
| Safety and Feasibility of Umbilical Cord Wharton's Jelly Allograft Injections for Lumbar Pain (NCT06361485) | R3 Stem Cell | 2024-03-25 |
| Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults (NCT06334393) | Valneva Austria GmbH | 2024-03-25 |
| A Phase 1/1b Study of IAM1363 in HER2 Cancers (NCT06253871) | Iambic Therapeutics, Inc | 2024-03-25 |
| Low Molecular Weight Heparin vs Direct Oral Anticoagulant After Bariatric Surgery (NCT06913595) | Cairo University | 2024-03-25 |
| Proof of Concept (PoC) Evaluation of Naloxone Unique Intramuscular (IM) Injection (NCT07180420) | STAT Therapeutics Inc | 2024-03-24 |
| Management of Bruxism in Patients With Implant Overdenture (NCT07361900) | Delta University for Science and Technology | 2024-03-24 |
| Comparison of Effectiveness of Disinfectants (NCT06811779) | Armed Forces Institute of Dentistry, Pakistan | 2024-03-24 |
| A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2102 in Healthy Adult (NCT06313697) | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 2024-03-23 |
| NAC Effect on Iron Overload and Blood Transfusion in β-thalassemia Major (NCT05777733) | Assiut University | 2024-03-23 |
| Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Mild, Moderate and Normal Hepatic Impairment (NCT06671509) | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | 2024-03-22 |
| Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic After Oral Administration of CKD-341 and D956 in Healthy Adults (NCT06281132) | Chong Kun Dang Pharmaceutical | 2024-03-22 |
| Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma (NCT05799612) | M.D. Anderson Cancer Center | 2024-03-22 |
| Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors (NCT06218914) | AstraZeneca | 2024-03-22 |
| Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies (NCT06316427) | Beijing GoBroad Hospital | 2024-03-22 |
| A Clinical Trial to Evaluate a High-Fat Meal and Omeprazole Enteric-coated Tablets on ASBK021 (NCT06322706) | Abbisko Therapeutics Co, Ltd | 2024-03-22 |
| Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors (NCT06380660) | Acerand Therapeutics (Shanghai) Limited | 2024-03-22 |
| A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment (NCT06318676) | Celgene | 2024-03-21 |
| Safety and Efficacy Study of NGGT001 in Bietti Crystalline Corneoretinal Dystrophy Subjects (NCT06706427) | NGGT (Suzhou) Biotechnology Co., Ltd. | 2024-03-21 |
| A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera (NCT06752746) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2024-03-21 |
| Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd (NCT06298084) | Gustave Roussy, Cancer Campus, Grand Paris | 2024-03-21 |
| Relative Bioavailability Study of CX2101A for the Treatment of COVID-19 (NCT06864182) | Heronova Pharmaceuticals | 2024-03-21 |
| First Time in Human Study of Long Acting VH4524184 Formulations (NCT06310551) | ViiV Healthcare | 2024-03-21 |
| IL13Rα2 CAR-T for Patients With r/r Glioma (NCT06355908) | Yang Zhang | 2024-03-21 |
| Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension (NCT06205628) | ADARx Pharmaceuticals, Inc. | 2024-03-21 |
| CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma (NCT06101381) | University of Sao Paulo | 2024-03-21 |
| COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER (NCT05692024) | Massachusetts General Hospital | 2024-03-21 |
| Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma (NCT06418113) | Hospital San Carlos, Madrid | 2024-03-21 |
| Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL (NCT06321289) | Chinese PLA General Hospital | 2024-03-20 |
| A Single, Ascending Dose Evaluation of the Safety, Pharmacokinetics of Methylone in Healthy Subjects (NCT06303648) | Transcend Therapeutics | 2024-03-20 |
| Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma (NCT06194929) | University of Utah | 2024-03-20 |
| A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943 (NCT06313528) | Eli Lilly and Company | 2024-03-20 |
| A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL (NCT06375733) | Genfleet Therapeutics (Shanghai) Inc. | 2024-03-20 |
| Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer (NCT06107868) | University Health Network, Toronto | 2024-03-20 |
| A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy (NCT06249438) | RenJi Hospital | 2024-03-20 |
| An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia (NCT06315283) | Teva Branded Pharmaceutical Products R&D LLC | 2024-03-20 |
| A Phase Ia/Ib Study of GH2616 Tablet in Subjects With Advanced Solid Tumors (NCT06329206) | Suzhou Genhouse Bio Co., Ltd. | 2024-03-20 |
| A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors (NCT06259552) | SparX Biotech(Jiangsu) Co., Ltd. | 2024-03-20 |
| ZL-82 Double-blind Clinical Trial (NCT06432738) | Chengdu Zenitar Biomedical Technology Co., Ltd | 2024-03-19 |
| Phase Ia Clinical Study of HDM1005 Injection (NCT06640647) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2024-03-19 |
| Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors (NCT06331559) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2024-03-19 |
| A Study of MK-6552 in Sleep Deprived Healthy Participants (MK-6552-003) (NCT06619665) | Merck Sharp & Dohme LLC | 2024-03-19 |
| A Phase 1 of CTX-8371 in Patients With Advanced Malignancies (NCT06150664) | Compass Therapeutics | 2024-03-19 |
| PK, PD and Safety of Tegoprazan 12.5 mg After Oral Administration in Healthy Subjects (NCT06332638) | HK inno.N Corporation | 2024-03-19 |
| Food Effect on the Bioavailability of 4-MUST, Tablets, 128 mg (NCT06342804) | Valenta Pharm JSC | 2024-03-19 |
| A Study to Evaluate Safety, Tolerability of LY4100511 (DC-853) in Healthy Asian and Non-Asian Participants (NCT06311656) | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | 2024-03-19 |
| A Study to Evaluate the Effect of Jaktinib on QT/QTc Interval in Healthy Participants (NCT06193148) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2024-03-19 |
| Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant (NCT06197672) | Huda Salman | 2024-03-19 |
| Phase I Clinical Trial of CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia (NCT07038941) | Beijing Dayspring Pharmaceutical Technology Co., Ltd | 2024-03-19 |
| A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in Healthy Chinese Participants (NCT06308523) | Alebund Pharmaceuticals | 2024-03-18 |
| A Clinical Study of Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-025) (NCT06691906) | Merck Sharp & Dohme LLC | 2024-03-18 |
| A Study to Assess the Effects of Itraconazole, Food, and pH on the Drug Levels of BMS-986368 in Healthy Participants (NCT06170723) | Celgene | 2024-03-18 |
| A Clinical Trial of Mass Balance of [14C] TQ05105 in Healthy Chinese Subjects (NCT07293390) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-03-18 |
| A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines (NCT06353971) | Jasper Therapeutics, Inc. | 2024-03-18 |
| B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies (NCT06191887) | Mayo Clinic | 2024-03-18 |
| A Phase I Clinical Study of Flonoltinib Maleate Tablets in Healthy Subjects (NCT06387966) | Chengdu Zenitar Biomedical Technology Co., Ltd | 2024-03-18 |
| A Trial Investigating Lu AF82422 in Healthy Chinese and Caucasian Adults (NCT06258720) | H. Lundbeck A/S | 2024-03-18 |
| Comparative Clinical Study to Evaluate the Possible Efficacy and Safety of Oral N-Acetyl Cysteine Versus Rectal Diclofenac in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis (NCT06252441) | Tanta University | 2024-03-16 |
| LEARNER- Low dosE AspiRiN prEterm tRial (Angola) (NCT06417411) | Instituto Nacional de Investigacao em Saude, Angola | 2024-03-16 |
| Effects of Different Doses of Intravenous Lidocaine Infusion on Peri-operative Pain and Incidence of Postoperative Chronic Pain Within ERAS Protocols, a Dose Finding Study. (NCT06431165) | Cairo University | 2024-03-15 |
| Localized Injection of Lidocaine and Glucocorticoid for Headache Treatment Phase 1 (NCT06462781) | The Cooper Health System | 2024-03-15 |
| A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma (NCT06097975) | Universitair Ziekenhuis Brussel | 2024-03-15 |
| Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 16055 NFL Delta Gly4 Env Protein Trimer and Trimer 4571 Combined With 3M-052-AF + Alum Adjuvant and Ad4-Env145NFL Viral Particles as Heterologous Prime-boost Regimens in Adult Participants Without HIV. (NCT06332339) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-03-15 |
| Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Placebo-Controlled Arm (NCT06219915) | University of Michigan | 2024-03-15 |
| CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults (NCT06305910) | OX2 Therapeutics | 2024-03-15 |
| SGLT2i in Diabetic Patients with Renal Transplantation (NCT06731231) | Ain Shams University | 2024-03-15 |
| A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's (NCT06309147) | Allyx Therapeutics | 2024-03-15 |
| A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer (NCT06308406) | Jiangsu HengRui Medicine Co., Ltd. | 2024-03-15 |
| Development of Virtual Reality-based Interventions to Strengthen Cognitive Skillsets Related to Attention Deficit Hyperactivity Disorder (ADHD): A Pilot Phase I and Randomized Controlled Phase II Trial (NCT05608434) | National Institute of Mental Health (NIMH) | 2024-03-15 |
| A Study of JMKX003948 Tablets in Patients With Renal Cell Carcinoma (NCT06321250) | Jemincare | 2024-03-14 |
| A Study of HS-10501 Tablets in Healthy Subjects (NCT06359600) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2024-03-14 |
| A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (NCT06313957) | Peking University Cancer Hospital & Institute | 2024-03-14 |
| A Thorough QT Study of ABBV-CLS-7262 in Healthy Subjects (NCT06310876) | Calico Life Sciences LLC | 2024-03-14 |
| A Study of HLX42 in Advanced/Metastatic Solid Tumors (NCT06210815) | Shanghai Henlius Biotech | 2024-03-14 |